Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.7091
+0.0038 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
December 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 08, 2023
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y
Via
Benzinga
Exposures
Product Safety
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
What's Going On With Bluebird Bio Stock?
December 08, 2023
Bluebird Bio, Inc.
Via
Benzinga
2 Biotech Stocks That Could Soar in December
November 26, 2023
These two biotechs have important catalysts coming up in December.
Via
The Motley Fool
Is Bluebird Bio Stock a Buy?
November 04, 2023
This biotech looks cheap, but is it a value trap?
Via
The Motley Fool
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
December 08, 2023
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
These 2 Stocks Could Be About to Soar: Are They Buys?
December 07, 2023
One thing is for certain -- both of these companies are innovators.
Via
The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
November 29, 2023
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.
Via
InvestorPlace
Where Will Bluebird Bio Be in 1 Year?
September 29, 2023
Things could get better for the biotech, but they could also get worse.
Via
The Motley Fool
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 24, 2023
Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares...
Via
Benzinga
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
November 20, 2023
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Via
The Motley Fool
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
November 08, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
November 07, 2023
The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024.
Via
The Motley Fool
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 07, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
bluebird bio, Inc.
Via
Business Wire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
October 30, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
October 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
October 17, 2023
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...
Via
Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
October 03, 2023
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.
Via
The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
September 20, 2023
These two biotechs have a lot in common, but one is much better capitalized.
Via
The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
September 12, 2023
These companies are innovators, something that can prove highly lucrative.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.